Skye Biologics Launches New Orthopedic BioECM® Placental Tissue Line

Skye will be introducing CryoMatrix™, ActiveBarrier™ & for in clinic applications new PX50™, part of its cutting edge & diverse line of Next Generation Active BioECM® Orthopedic (ECM is a dynamic protein system that provides the foundation for all of the body’s organs and tissues) biologic products derived from placental tissues at the 2014 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) on March 11-15th in New Orleans.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
'Skye is very excited to showcase at AAOS and unveil to the industry CryoMatrix™, ActiveBarrier™ & for in clinic applications PX50™, its new Active BioECM® Product offering - the next generation and most diverse biologics offering.' - Chris Sharp

Redondo Beach, CA (PRWEB) March 12, 2014

Skye OrthoBiologics, LLC is a regenerative and osteobiologic solutions Biotechnology Company engaged in the development and commercialization of novel human based active Extracellular Matrix (ECM) biologic products. Skye is dedicated to creating, engineering and advancing industry-leading biologics under it’s new BioECM® product line.

Skye will be introducing CryoMatrix™, ActiveBarrier™ & for in clinic applications new PX50™, part of its cutting edge & diverse line of Next Generation Active BioECM® Orthopedic (ECM is a dynamic protein system that provides the foundation for all of the body’s organs and tissues) biologic products derived from placental tissues at the 2014 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) on March 11-15th in New Orleans.

Skye will also be displaying its entire osteobiologics, sports medicine bio-implants and placental-tissue based product portfolio at the meeting.

Skye is actively looking to expand its national and international distribution network for CryoMatrix™, ActiveBarrier™ & PX50™ along with private label opportunities with complimentary sports medicine focused companies.

Conference attendees: Skye invites all Surgeons, Reps, and Distributors to visit out Booth #7220.

“Skye is very excited to showcase at AAOS this year and unveil to the industry CryoMatrix™, ActiveBarrier™ & for in clinic applications PX50™ its new Active BioECM® Product offering - the next generation and most diverse biologics offering including our novel and tailored placental tissues for orthopedics. These biologics are demonstrating to be an ideal solution for the treatment of many sports medicine injuries,” commented CEO, Chris Sharp “We have developed one of the industries most diverse Active ECM biologic lines through our proprietary processing techniques and are thrilled to be sharing them with the Orthopedic community at this meeting. Our mission is to further advance our BioECM® line of novel tissue-based products with the goal of enhancing the quality of patient care in a broad range of clinical applications.”

About SKYE:
Skye Orthobiologics, LLC is a leading osteobiologics and regenerative biologics company engaged in the research, development and commercialization of novel biologic products derived from natural biologics and placental tissues. Our research, development and advancement efforts are focused on the extracellular nature and regenerative potential of placental tissues given their complex protein biologic structure that has demonstrated excellent clinical effectiveness over the last 10 years.

Skye continues to advance The Power of the Body. The Innovation of Science.® by focusing on the regenerative potential of the human body. For more information, visit our website at http://www.skyebiologics.com.

Marketing / Sales Enquiries:
Chris Sharp
CEO
310.944.5402
csharp(at)skyebiologics(dot)com

Forward-looking statement
Any forward-looking statement is based on information available to Skye Orthobiologics, LLC as of the date of the statement. All written or oral forward-looking statements attributable to Skye Orthobiologics LLC are qualified by this caution. Skye does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Skye’s expectations.


Contact